Skip to main content
Signal8
Launch Terminal

Aurinia Pharmaceuticals Inc. (AUPH)

Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Aurinia Pharmaceuticals Inc. logo

Aurinia Pharmaceuticals Inc.

NASDAQ:AUPHHealthcare
-3.25%$16.65
AH$16.68+0.18%vs close
Mkt Cap$2.23B
Float107.31M
O/S134M
Vol
$ Vol
RVOL
Inst Own59.1%
SI7.3%
Earnings
Dilution
Aurinia Pharmaceuticals Inc. logoNASDAQ:AUPH$16.65-3.25%
Phase Distribution
19 lead-sponsored trials·2 active·13 completed
Phase 12
Phase 1/21
Phase 25
Phase 2/31
Phase 38
Phase 41
Not applicable1
(1 more as collaborator)
Status Overview
Recruiting2
Completed13
Stopped4

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Recruiting

    PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

    LUPKYNIS, belimumab, obinutuzumab or anifrolumab

    Lupus Nephritis

    Enrollment
    150
    Start
    Apr 2026
    Primary Completion
    Mar 2029est.
    Completion
    Mar 2029est.
    NCT07611214
  • Phase 3
    Completed

    Randomized Placebo-controlled Study of ISA247 in Plaque Psoriasis

    voclosporin, Placebo

    Psoriasis

    Enrollment
    451
    Start
    Dec 2004
    Primary Completion
    Oct 2005
    Completion
    Oct 2005
    NCT00244842
  • Phase 3
    Completed

    A 36-Week Extension to Protocol ISA04-03

    voclosporin

    Psoriasis

    Enrollment
    309
    Start
    Sep 2005
    Primary Completion
    Jul 2006
    Completion
    Jul 2006
    NCT00258713
  • Phase 3
    Completed

    Randomized, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis Patients

    voclosporin, Ciclosporin

    Psoriasis

    Enrollment
    642
    Start
    Dec 2006
    Primary Completion
    Dec 2008
    Completion
    Dec 2008
    NCT00408187
  • Phase 3
    Withdrawn

    Safety and Efficacy Study of Voclosporin and Tacrolimus in Transplantation

    voclosporin, tacrolimus

    Renal Transplantation

    Enrollment
    0
    Start
    Mar 2013
    Primary Completion
    Dec 2015est.
    Completion
    Dec 2015est.
    NCT01586845
  • Phase 3
    Completed

    Aurinia Renal Response in Active Lupus With Voclosporin

    Voclosporin, Placebo Oral Capsule

    Lupus Nephritis

    Enrollment
    358
    Start
    May 2017
    Primary Completion
    Sep 2019
    Completion
    Oct 2019
    NCT03021499
  • Phase 3
    Completed

    Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin

    Voclosporin, Placebo Oral Capsule

    Lupus Nephritis

    Enrollment
    216
    Start
    Sep 2019
    Primary Completion
    Oct 2021
    Completion
    Oct 2021
    NCT03597464
  • Phase 3
    Terminated

    Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis

    Voclosporin, Placebo Oral Capsule

    Adolescent Lupus Nephritis, Pediatric Lupus Nephritis

    Enrollment
    9
    Start
    Oct 2023
    Primary Completion
    Jul 2025
    Completion
    Jul 2025
    NCT05288855
  • Phase 3
    Terminated

    Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis

    voclosporin

    Adolescent Lupus Nephritis, Pediatric Lupus Nephritis

    Enrollment
    4
    Start
    Mar 2024
    Primary Completion
    Jul 2025
    Completion
    Jul 2025
    NCT05962788
  • Phase 2/3
    Completed

    Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome

    0.05% Voclosporin Ophthalmic Solution (VOS), 0.10% VOS

    Dry Eye Syndrome, Keratoconjunctivitis Sicca

    Enrollment
    508
    Start
    Oct 2019
    Primary Completion
    Sep 2020
    Completion
    Oct 2020
    NCT04147650
  • Phase 2
    Completed

    Study of ISA247 (Voclosporin) in De Novo Renal Transplantation

    Voclosporin, tacrolimus

    Kidney Diseases

    Enrollment
    334
    Start
    Jan 2006
    Primary Completion
    Jul 2009
    Completion
    Jul 2009
    NCT00270634
  • Phase 2
    Completed

    AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)

    Voclosporin High Dose, Voclosporin Low Dose

    Lupus Nephritis

    Enrollment
    265
    Start
    Jun 2014
    Primary Completion
    Jul 2016
    Completion
    Jan 2017
    NCT02141672
  • Phase 2
    Completed

    Aurinia Early Urinary Protein Reduction Predicts Response

    voclosporin

    Lupus Nephritis

    Enrollment
    10
    Start
    Jun 2015
    Primary Completion
    Dec 2016
    Completion
    Feb 2017
    NCT02949973
  • Phase 2
    Completed

    Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease

    Voclosporin Ophthalmic Solution, Restasis®

    Dry Eye

    Enrollment
    100
    Start
    Aug 2018
    Primary Completion
    Nov 2018
    Completion
    Dec 2018
    NCT03597139
  • Phase 2
    Terminated

    Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis

    Voclosporin

    Focal Segmental Glomerulosclerosis

    Enrollment
    5
    Start
    Jun 2018
    Primary Completion
    May 2020
    Completion
    May 2020
    NCT03598036
  • Phase 1/2
    Recruiting

    Study of Aritinercept in Patients With Generalized Myasthenia Gravis

    Aritinercept

    Myasthenia Gravis, Generalized

    Enrollment
    81
    Start
    Apr 2026
    Primary Completion
    Mar 2029est.
    Completion
    Mar 2029est.
    NCT07596901
  • Phase 1
    Completed

    Voclosporin in Healthy Japanese Volunteers

    Voclosporin

    Volunteers

    Enrollment
    40
    Start
    Oct 2016
    Primary Completion
    Dec 2016
    Completion
    Dec 2016
    NCT02949999
  • Phase 1
    Completed

    Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin

    Simvastatin, Voclosporin

    Drug-drug Interaction

    Enrollment
    24
    Start
    Jan 2022
    Primary Completion
    Apr 2022
    Completion
    Apr 2022
    NCT05306379
  • Observational
    Completed

    A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US

    LUPKYNIS

    Lupus Nephritis

    Enrollment
    229
    Start
    Apr 2022
    Primary Completion
    Jan 2025
    Completion
    Jan 2025
    NCT05337124
Search ClinicalTrials.gov for “Aurinia Pharmaceuticals”